Trial · NCT03000439
Results by group1,057
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 1,057
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Systemic Juvenile Idiopathic Arthritis (sJIA) Disease Flare: Double-Blind Phase | Tofacitinib 5mg BID DB | NA | 95% Confidence Interval 186.0 to NA | Days | |
| Time to Systemic Juvenile Idiopathic Arthritis (sJIA) Disease Flare: Double-Blind Phase | Placebo DB | 295.0 | 95% Confidence Interval 99.0 to NA | Days | |
| Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase | Tofacitinib 5mg BID DB | DB Week 4 | 7.1 | Percentage probability of occurrence | |
| Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase | Placebo DB | DB Week 4 | 6.5 | Percentage probability of occurrence | |
| Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase | Tofacitinib 5mg BID DB | DB Week 8 | 14.3 | Percentage probability of occurrence | |
| Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase | Placebo DB | DB Week 8 | 22.6 | Percentage probability of occurrence | |
| Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase | Tofacitinib 5mg BID DB | DB Week 12 | 21.4 | Percentage probability of occurrence | |
| Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase | Placebo DB | DB Week 12 | 32.3 | Percentage probability of occurrence | |
| Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase | Tofacitinib 5mg BID DB | DB Week 16 | 25.0 | Percentage probability of occurrence | |
| Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase | Placebo DB | DB Week 16 | 38.7 | Percentage probability of occurrence | |
| Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase | Tofacitinib 5mg BID DB | DB Week 20 | 32.1 | Percentage probability of occurrence | |
| Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase | Placebo DB | DB Week 20 | 45.4 | Percentage probability of occurrence | |
| Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase | Tofacitinib 5mg BID DB | DB Week 24 | 32.1 | Percentage probability of occurrence | |
| Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase | Placebo DB | DB Week 24 | 45.4 | Percentage probability of occurrence | |
| Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase | Tofacitinib 5mg BID DB | DB Week 28 | 35.9 | Percentage probability of occurrence | |
| Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase | Placebo DB | DB Week 28 | 45.4 | Percentage probability of occurrence | |
| Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase | Tofacitinib 5mg BID DB | DB Week 32 | 35.9 | Percentage probability of occurrence | |
| Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase | Placebo DB | DB Week 32 | 49.9 | Percentage probability of occurrence | |
| Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase | Tofacitinib 5mg BID DB | DB Week 36 | 40.5 | Percentage probability of occurrence | |
| Probability of Occurrence of sJIA Disease Flare at DB Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: Double-Blind Phase | Placebo DB | DB Week 36 | 49.9 | Percentage probability of occurrence |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03000439/results